Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

Rhea-AI Summary

Certara (Nasdaq:CERT) announced a collaboration with NVIDIA to enhance its open integrated AI platform using the NVIDIA BioNeMo Agent Toolkit. The partnership connects Certara’s biosimulation software, proprietary datasets, and regulatory expertise with AI agents that can autonomously generate specialized insights across the drug discovery and development lifecycle.

These agents will reason over models and clinical data to optimize dosing, simulate trials, evaluate ADMET properties, and prepare regulatory-ready evidence, while keeping scientists in the decision-making loop.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Integration of NVIDIA BioNeMo Agent Toolkit into Certara’s AI platform
• AI agents unified with biosimulation models, datasets, and regulatory expertise
• Support for insights across dosing, clinical datasets, trial simulation, ADMET, and regulatory evidence
• Focus on scientist-in-the-loop workflows for speed, scale, and reproducibility

Negative

• None.

What This Means

Certara’s integration of NVIDIA’s BioNeMo Agent Toolkit into its AI platform extends earlier AI work...

Analysis

Certara’s integration of NVIDIA’s BioNeMo Agent Toolkit into its AI platform extends earlier AI work that previously coincided with a 2.38% average move. Investors may weigh long‑term platform benefits against elevated short positioning and execution on commercial adoption.

Previous AI Reports

1 past event · Latest: Oct 30 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 30	AI platform launch	Positive	+2.4%	Introduced AI‑powered QSP platform to scale biosimulation across development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AI‑themed launches for Certara have previously drawn a modestly positive next‑day price reaction.

Historical Comparison

+2.4% avg move · Over the past six months, Certara had 1 AI‑tagged event, which typically moved the stock about 2.38%...

AI

+2.4%

Average Historical Move AI

Over the past six months, Certara had 1 AI‑tagged event, which typically moved the stock about 2.38% the next day. This NVIDIA BioNeMo integration continues that AI focus and is consistent with prior innovation‑driven announcements.

Same‑tag history shows Certara moving from launching an AI‑driven QSP platform toward expanding its AI stack via NVIDIA BioNeMo, suggesting a continuing build‑out of AI‑enabled biosimulation capabilities.

Regulatory & Risk Context

Short Interest: 24.76%

Short Interest

24.76% of float

0% 15% 30%+

moderate as of 2026-06-15 Days to cover: 7.25

Short interest appears elevated, indicating positioning that could amplify volatility around news and create both squeeze risk and vulnerability if sentiment weakens.

Key Terms

agentic ai, biosimulation, admet, systems pharmacology models, +1 more

5 terms

agentic ai technical

"Agentic AI combined with Certara's world-class scientists, validated models, and data"

Agentic AI refers to computer systems that can make their own decisions and take actions without needing someone to tell them what to do each time. It's like giving a robot a degree of independence to solve problems or achieve goals on its own, which matters because it could change how we work and interact with technology in everyday life.

biosimulation technical

"working alongside Certara's biosimulation models, regulatory expertise, and scientific teams"

Biosimulation is the use of computer models to mimic how drugs, cells, or whole biological systems behave, predicting outcomes like effectiveness, side effects, or disease progression. Think of it as a flight or weather simulator for biology that lets researchers test ideas virtually before real-world trials. Investors care because accurate biosimulation can cut development time and cost, lower the risk of failed trials, and improve the odds that a program will reach the market.

admet medical

"evaluating ADMET properties, assembling regulatory-ready evidence, and exploring"

ADMET is the shorthand for a drug candidate’s absorption, distribution, metabolism, excretion and toxicity — the key ways it behaves and is processed in the body. Investors watch ADMET because favorable results indicate a medicine is likely to reach its target, be safe enough, and survive development and regulatory review; poor ADMET is a common, early reason a program fails, like a car that looks good but won’t run reliably or safely.

systems pharmacology models medical

"optimizing a dosing strategy with systems pharmacology models, interrogating a clinical dataset"

Computational frameworks that bring together biological knowledge, drug action, and disease processes to simulate how a medicine affects the whole body over time. Think of them like a flight simulator for drugs: they let researchers predict likely benefits, side effects, dosing and trial outcomes before large, costly studies, so investors can better understand development risks, timelines, and the strength of scientific evidence behind a drug program.

ai agent technical

"The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous"

An AI agent is software that uses artificial intelligence to observe data, decide on actions, and carry them out with little or no human intervention. For investors, AI agents matter because they can automate tasks like trading, customer support, or data analysis, potentially boosting efficiency, lowering costs, and changing a company’s competitive edge—much like a tireless, adaptable assistant running parts of a business continuously.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences

RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.

The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous life sciences scientist, providing access to NVIDIA’s full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insight generation.

“Agentic AI combined with Certara's world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need to generate integrated evidence for regulators,” said Jon Resnick, Chief Executive Officer. “Our collaboration with NVIDIA intends to bring frontier AI to life sciences responsibly, at scale, and with the scientific rigor the industry demands.”

Specialized AI agents will reason over Certara's scientific models, data, and domain expertise to produce insights across the full development continuum — optimizing a dosing strategy with systems pharmacology models, interrogating a clinical dataset, simulating patient and trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence, and exploring early discovery hypotheses. Agentic AI augments biosimulation experts and scientific teams, delivering faster access to insights while keeping scientists at the center of decision-making.

“We believe it will become increasingly possible to computationally simulate human biology in ways that will transform the discovery and development of new medicines,” said Chris Bouton, Chief Technology Officer, Chief AI Officer. “Our collaboration with NVIDIA and addition of the BioNeMo Agent Toolkit to the integrated platform helps accelerate that vision.”

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding Certara’s integrated platform, the collaboration with NVIDIA, the integration of NVIDIA BioNeMo Agent Toolkit, and the anticipated benefits, capabilities, availability, and impact of these technologies. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Certara undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Sheila Rocchio
Sheila.rocchio@certara.com

FAQ

What did Certara (NASDAQ:CERT) announce about the NVIDIA BioNeMo Agent Toolkit on July 7, 2026?

Certara announced that it is integrating the NVIDIA BioNeMo Agent Toolkit into its open AI platform. According to Certara, this toolkit will function as an agentic framework alongside its biosimulation software and datasets to generate specialized life sciences insights across drug discovery and development.

How will integrating NVIDIA BioNeMo Agent Toolkit benefit Certara (CERT) drug discovery and development?

The integration is intended to accelerate insight generation across the full development continuum. According to Certara, AI agents will optimize dosing strategies, interrogate clinical datasets, simulate patient and trial scenarios, evaluate ADMET properties, and help assemble regulatory-ready evidence within its unified AI-driven biosimulation platform.

What is agentic AI in Certara’s (CERT) platform and how does it support scientists?

Agentic AI in Certara’s platform uses specialized AI agents that can autonomously reason over models and data. According to Certara, these agents augment biosimulation experts, providing faster, scalable, and reproducible insights while keeping scientists in the loop for critical life sciences decision-making.

How will Certara (CERT) use AI agents across the drug development continuum?

Certara plans to deploy AI agents across early discovery through clinical development and regulatory evidence generation. According to Certara, agents will explore discovery hypotheses, refine dosing via systems pharmacology models, analyze clinical datasets, simulate trials, assess ADMET, and help assemble integrated evidence packages.

What does the collaboration between Certara (CERT) and NVIDIA mean for life sciences innovation?

The collaboration aims to bring frontier AI capabilities to life sciences in a responsible, scalable way. According to Certara, combining BioNeMo with its validated models and expertise supports the long-term vision of computationally simulating human biology to transform medicine discovery and development.

How does Certara’s (CERT) AI platform keep scientists central while using agentic AI?

Certara’s approach is described as keeping the scientist in the loop while leveraging AI for speed and scale. According to Certara, agentic AI augments, rather than replaces, biosimulation experts, enabling reproducible, AI-assisted workflows for regulatory-grade evidence and complex drug development decisions.